Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

NCT05946460 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Aumolertinib

Sponsor

The First Affiliated Hospital of Guangzhou Medical University